Preferred Label : Tildacerfont;
NCIt definition : An orally bioavailable, selective nonsteroidal antagonist of the corticotropin-releasing
factor type-1 (CRF1; CRF-1) receptor, that can potentially be used to prevent excess
androgen production in congenital adrenal hyperplasia (CAH). Upon oral administration,
tildacerfon targets, binds to and inhibits the CRF1 receptor located in the pituitary
gland. This reduces adrenocorticotropic hormone (ACTH) secretion and reduces the overproduction
of adrenal androgens. CRF is a key regulator of the hypothalamic-pituitary-adrenal
(HPA) axis and stimulates ACTH release from the anterior pituitary. CAH comprises
a set of enzymatic defects in the cortisol synthetic pathway. A decrease in adrenal
cortisol production impairs negative feedback on the HPA axis, which increases production
of CRF and ACTH, the primary stimulus for cortisol and 19-carbon steroid production
in the adrenal cortex.;
UNII : 09QCEV5481;
InChIKey : CLKXPWDYEYIPFS-UHFFFAOYSA-N;
CAS number : 1014983-00-6;
Molecule name : SPR 001; LY 2371712; LY-2371712; SPR-001;
NCI Metathesaurus CUI : CL1405995;
Origin ID : C171816;
UMLS CUI : C5419318;
Semantic type(s)
- concept_is_in_subset
